Yahoo
NYSE - Delayed Quote USD

Artivion, Inc. (AORT)

22.58 -0.86 (-3.67%)
At close: October 30 at 4:00:02 PM EDT
22.58 0.00 (0.00%)
After hours: October 30 at 4:01:06 PM EDT
Trade AORT on Coinbase
Chart Range Bar
Loading chart for AORT
Chart does not reflect overnight price.
  • Previous Close 23.44
  • Open 23.62
  • Bid 22.60 x 40000
  • Ask 30.00 x 10000
  • Day's Range 21.85 - 23.51
  • 52 Week Range 19.16 - 48.25
  • Volume 627,382
  • Avg. Volume 624,946
  • Market Cap (intraday) 1.101B
  • Beta (5Y Monthly) 1.22
  • PE Ratio (TTM) --
  • EPS (TTM) -0.07
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 40.91
  • Zacks Rating Neutral

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

artivion.com

1,800

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AORT
50.49%
S&P 500 (^GSPC)
10.73%

1-Year Return

AORT
50.54%
S&P 500 (^GSPC)
11.11%

3-Year Return

AORT
79.35%
S&P 500 (^GSPC)
81.91%

5-Year Return

AORT
9.40%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 125.76M
Earnings -13.51M
Profit Margin -10.74%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
50M
100M
-10.0%
-5.0%
0.0%
5.0%

Analyst Insights

View More

Analyst Price Targets

31.00
40.91 Average
22.58 Current
48.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/20/2026
Analyst Jefferies
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 31

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.67%

  • Return on Assets (ttm)

    2.56%

  • Return on Equity (ttm)

    -0.73%

  • Revenue (ttm)

    471.47M

  • Net Income Avi to Common (ttm)

    -3.19M

  • Diluted EPS (ttm)

    -0.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    77.32M

  • Total Debt/Equity (mrq)

    91.56%

  • Levered Free Cash Flow (ttm)

    13.1M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: